AI Article Synopsis

  • This study compared double low-dose hepatic multiphase CT (DLDCT) with standard-dose CT (SDCT) in terms of image quality and detectability for patients with chronic liver disease.
  • DLDCT showed a significant reduction in radiation exposure (36.6%) and iodine concentration (22.9%) while maintaining higher overall image quality scores and better lesion contrast-to-noise ratio compared to SDCT.
  • The findings suggest that DLDCT using a deep-learning model can effectively assess hepatic lesions without compromising image quality or detectability.

Article Abstract

Background: This study investigated the image quality and detectability of double low-dose hepatic multiphase CT (DLDCT, which targeted about 30% reductions of both the radiation and iodine concentration) using a vendor-agnostic deep-learning-based contrast-boosting model (DL-CB) compared to those of standard-dose CT (SDCT) using hybrid iterative reconstruction.

Methods: The CT images of 73 patients with chronic liver disease who underwent DLDCT between June 2023 and October 2023 and had SDCT were analyzed. Qualitative analysis of the overall image quality, artificial sensation, and liver contour sharpness on the arterial and portal phase, along with the hepatic artery clarity was conducted by two radiologists using a 5-point scale. For quantitative analysis, the image noise, signal-to-noise ratio, and contrast-to-noise ratio were measured. The lesion conspicuity was analyzed using generalized estimating equation analysis. Lesion detection was evaluated using the jackknife free-response receiver operating characteristic figures-of-merit.

Results: Compared with SDCT, a significantly lower effective dose (16.4 ± 7.2 mSv vs. 10.4 ± 6.0 mSv, 36.6% reduction) and iodine amount (350 mg iodine/mL vs. 270 mg iodine/mL, 22.9% reduction) were utilized in DLDCT. The mean overall arterial and portal phase image quality scores of DLDCT were significantly higher than SDCT (arterial phase, 4.77 ± 0.45 vs. 4.93 ± 0.24, AUC 0.572 [95% CI, 0.507-0.638]; portal phase, 4.83 ± 0.38 vs. 4.92 ± 0.26, AUC 0.535 [95% CI, 0.469-0.601]). Furthermore, DLDCT showed significantly superior quantitative results for the lesion contrast-to-noise ratio (7.55 ± 4.55 vs. 3.70 ± 2.64, < 0.001) and lesion detectability (0.97 vs. 0.86, = 0.003).

Conclusions: In patients with chronic liver disease, DLDCT using DL-CB can provide acceptable image quality without impairing the detection and evaluation of hepatic focal lesions compared to SDCT.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11507254PMC
http://dx.doi.org/10.3390/diagnostics14202308DOI Listing

Publication Analysis

Top Keywords

image quality
20
chronic liver
12
liver disease
12
portal phase
12
lesion detectability
8
hepatic multiphase
8
deep-learning-based contrast-boosting
8
contrast-boosting model
8
patients chronic
8
analysis image
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!